Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
- Sunil Shrestha,
- Januka Khatri,
- Sujyoti Shakya,
- Krisha Danekhu,
- Asmita Priyadarshini Khatiwada,
- Ranjit Sah
- Monash University Malaysia,
- Kathmandu University,
- Nepal Health Research and Innovation Foundation,
- Nobel College,
- Tribhuvan University Teaching Hospital,
- National Public Health Laboratory
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 376-382 (7 pages)Journal (Volume, Issue Number)
Drugs and Therapy Perspectives (Volume 37, Issue 8)Publication milestones
- Published - 08/2021
Publication status
ISSN
1172-0360Publication IDs
- Scopus: 85111895141
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.
Access to documents
Publication metrics
Metrics
Sustainable Development Goals
- SDG 3 Good Health and Well
